BACK
TO MAIN
PAGE

Epstein-Barr virus (EBV) infection

General Information

Epstein-Barr virus (EBV) is a member of the herpes virus family. ​

EBV is the first human tumor virus discovered and is strongly implicated in the etiology of multiple lymphoid and epithelial cancers, such as Burkitt lymphoma (BL), Hodgkin lymphoma (HL), post-transplant lymphoproliferative disorder (PTLD), nasopharyngeal carcinoma (NPC), and gastric carcinoma (GC). ​

There are no vaccines or treatments against EBV infection. ​

Symptoms

EBV is also the primary cause of infectious mononucleosis that could cause persistent fatigue for up to 6 months and cause severe neurologic, hematologic, or liver complications.​

EBV has been shown to play a critical role in the pathogenesis of multiple sclerosis.​

Show More

Epidemiology

Up to 70% of adolescents and young adults in developed countries suffer from infectious mononucleosis.​

Each year EBV associated cancers account for over 200,000 new cases of cancer and cause 150,000 deaths worldwide. 

Vaccines
Pipeline

1
Vaccines in
the pipeline

Technology Platforms

  • mRNA (1)

DEVELOPMENT PHASES

  • Phase I (1)

TRIAL POPULATION

  • Adults (1)

Sources: 
https://www.cdc.gov/epstein-barr/about-ebv.html
https://doi.org/10.3389/fimmu.2021.734471​​
[Accessed: November 2022]

Vaccines Europe Pipeline Review

Download our pipeline review